Nicolai Tegn1,2, Michael Abdelnoor3, Lars Aaberge1, Anette Hylen Ranhoff4, Knut Endresen1, Erik Gjertsen5, Rita Skårdal1, Lars Gullestad1,2, Bjørn Bendz1,2. 1. Department of Cardiology, Oslo University Hospital, Rikshospitalet, Oslo, Norway. 2. Faculty of Medicine, University of Oslo, Norway. 3. Centre for Biostatistics and Epidemiology, Oslo University Hospital, Ullevål, Oslo, Norway. 4. Diakonhjemmet Hospital and Department of Clinical Science, University of Bergen, University of Bergen, Bergen, Norway. 5. Department of Cardiology, Drammen Hospital, Drammen, Norway.
Abstract
Objective: in the After Eighty study (ClinicalTrials.gov.number, NCT01255540), patients aged 80 years or more, with non-ST-elevation myocardial infarction (NSTEMI), and unstable angina pectoris (UAP), were randomised to either an invasive or conservative management approach. We sought to compare the effects of these management strategies on health related quality of life (HRQOL) after 1 year. Methods: the After Eighty study was a prospective randomised controlled multicenter trial. In total, 457 patients aged 80 or over, with NSTEMI or UAP, were randomised to either an invasive strategy (n = 229, mean age: 84.7 years), involving early coronary angiography, with immediate evaluation for percutaneous coronary intervention, coronary artery bypass graft, optimal medical therapy, or to a conservative strategy (n = 228, mean age: 84.9 years). The Short Form 36 health survey (SF-36) was used to assess HRQOL at baseline, and at the 1-year follow-up. Results:baseline SF-36 completion was achieved for 208 and 216 patients in the invasive and conservative groups, respectively. A total of 137 in the invasive group and 136 patients in the conservative group completed the SF-36 form at follow-up. When comparing the changes from follow-up to baseline (delta) no significant changes in quality-of-life scores were observed between the two strategies in any of the domains, expect for a small but statistically significant difference in bodily pain. This difference in only one of the SF-36 subscales may not necessarily be clinically significant. Conclusion: from baseline to the 1 year follow-up, only minor differences in change of HRQOL as measured by SF-36 were seen by comparing an invasive and conservative strategy. ClinicalTrials.gov identifier: NCT01255540.
RCT Entities:
Objective: in the After Eighty study (ClinicalTrials.gov.number, NCT01255540), patients aged 80 years or more, with non-ST-elevation myocardial infarction (NSTEMI), and unstable angina pectoris (UAP), were randomised to either an invasive or conservative management approach. We sought to compare the effects of these management strategies on health related quality of life (HRQOL) after 1 year. Methods: the After Eighty study was a prospective randomised controlled multicenter trial. In total, 457 patients aged 80 or over, with NSTEMI or UAP, were randomised to either an invasive strategy (n = 229, mean age: 84.7 years), involving early coronary angiography, with immediate evaluation for percutaneous coronary intervention, coronary artery bypass graft, optimal medical therapy, or to a conservative strategy (n = 228, mean age: 84.9 years). The Short Form 36 health survey (SF-36) was used to assess HRQOL at baseline, and at the 1-year follow-up. Results: baseline SF-36 completion was achieved for 208 and 216 patients in the invasive and conservative groups, respectively. A total of 137 in the invasive group and 136 patients in the conservative group completed the SF-36 form at follow-up. When comparing the changes from follow-up to baseline (delta) no significant changes in quality-of-life scores were observed between the two strategies in any of the domains, expect for a small but statistically significant difference in bodily pain. This difference in only one of the SF-36 subscales may not necessarily be clinically significant. Conclusion: from baseline to the 1 year follow-up, only minor differences in change of HRQOL as measured by SF-36 were seen by comparing an invasive and conservative strategy. ClinicalTrials.gov identifier: NCT01255540.
Authors: Greg B Mills; Hanna Ratcovich; Jennifer Adams-Hall; Benjamin Beska; Emma Kirkup; Daniell E Raharjo; Murugapathy Veerasamy; Chris Wilkinson; Vijay Kunadian Journal: Eur Heart J Open Date: 2021-12-17
Authors: Nicolai Tegn; Christian Eek; Michael Abdelnoor; Lars Aaberge; Knut Endresen; Rita Skårdal; Erlend Sturle Berg; Lars Gullestad; Bjørn Bendz Journal: Open Heart Date: 2020-07
Authors: Billingsley Kaambwa; Hailay Abrha Gesesew; Matthew Horsfall; Derek Chew Journal: Int J Environ Res Public Health Date: 2020-09-21 Impact factor: 3.390